Petra Ahokas, Laboratory Manager, has over 10 years of experience working in laboratories, both as a research assistant and as a scientist, mostly in the field of cancer research. She joined Valo Therapeutics in 2018 and was tasks with opening and managing Valo's new research and development laboratory. Before joining Valo Therapeutics, Petra worked in cancer research at the University of Helsinki and extensively with oncolytic viruses as a Research Scientist at Oncos Therapeutics (now Targovax).
The NeoAg Summit (formerly Neoantigen Summit) is the 3rd annual industry focused meeting dedicated to advancing neoantigen based cancer vaccines and cell therapies. Our aim is to bring together the pioneers supercharging next generation immunotherapies to accelerate safe, effective and scalable neoantigen-based therapies.
The Cancer Research Institute (CRI), the Association for Cancer Immunotherapy (CIMT), the European Academy of Tumor Immunology (EATI), and the American Association for Cancer Research (AACR) are proud to once again join forces to present the International Cancer Immunotherapy Conference. The program will focus on “Translating Science into Survival” and feature talks from more than 60 leaders in the field covering all areas of inquiry in cancer immunology and immunotherapy.
SITC 2018 is the leading destination for scientific exchange, education and networking in the cancer immunotherapy field.
Scott Cuthill, Chief Business Officer, has over 20 years experience in the Pharma and Biotech industry, gained initially in a variety of R&D roles at Roche and OSI Pharmaceuticals in the UK, in the viral disease and oncology disease areas. Scott joined Valo Tx in 2018 and has considerable business development experience, having successfully led both in and out-licensing deals for assets ranging from early stage platform technologies to marketed products.
The BIO International Convention is hosted by the Biotechnology Innovation Organization (BIO), which represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations.
Professor Zeps has been recently appointed as the inaugural Group Director of Research for Epworth HealthCare in Melbourne, Australia. Prior to that he was the Director of Research at SJG HealthCare from 2012 to 2016 and head of their cancer translational research program from 2008. He is an Adjunct Professor at the Monash University Eastern Clinical School.
He was a member of the Australian Health Ethics Committee from 2006-2012 and the Research Committee of the National Health and Medical Research Council (NHMRC) of Australia from 2009-2015.
Erkko Ylösmäki, Senior Scientist, has over 12 years of experience in the development of oncolytic viruses for cancer immunotherapy. During his academic career, he has developed various microRNA-regulated novel oncolytic viruses (both DNA and RNA viruses), for increased safety as well as potency. He has also developed numerous new oncolytic virus-based (e.g. Vaccinia and Herpes Simplex Virus type 1) cancer vaccine platforms that can dramatically enhance CD8+ T cell-specific anti-tumour immunity.
Oncolytic virotherapy represents an exciting new area of cancer treatment which exploits a virus’s ability to selectively replicate and kill tumor tissue while stimulating a patient-specific immune response against cancer. Interest in the field is at an all-time high following several significant deals. However, questions still remain around delivery, product and clinical development, pre-clinical modelling, scale-up, manufacturing and suitable commercial models.